WILMINGTON, Mass. / Jul 19, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2023 financial results on Wednesday, August 9th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 9th, at 8:30 a.m. ET.
Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website.
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
| Last Trade: | US$158.04 |
| Daily Change: | -1.36 -0.85 |
| Daily Volume: | 615,685 |
| Market Cap: | US$7.760B |
June 16, 2025 May 28, 2025 April 29, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
